Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13459727 | 0.75 | CRHR1 (0.40) | CRHR1SMN1; SMN2 | |
| SCHEMBL13199946 | 0.73 | SMN1; SMN2 (0.46) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2085479 | 0.69 | SMN1; SMN2 (0.34) | CRHR1SMN1; SMN2 | |
| SCHEMBL5143754 | 0.68 | CRHR1 (0.73) | CRHR1 | |
| SCHEMBL13459230 | 0.68 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL3293146 | 0.68 | UTS2R (0.41) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3285073 | 0.66 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL13459227 | 0.64 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL8489711 | 0.63 | MEN1 (0.50) | CRHR1MEN1NPC1AGTR1RAB9A | |
| SCHEMBL2082782 | 0.61 | SMN1; SMN2 (0.44) | CRHR1MEN1KMT2AALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714009-B2 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | NPY4R, NR4A3, NR3C2 | CRHR1 4/4885MEN1 1568/4885NPC1 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.